🎉 M&A multiples are live!
Check it out!

TOWA Pharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for TOWA Pharmaceutical and similar public comparables like Pharming, Benevolent AI, and Vivoryon Therapeutics.

TOWA Pharmaceutical Overview

About TOWA Pharmaceutical

TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.


Founded

1957

HQ

Japan
Employees

3.1K+

Financials

LTM Revenue $1.7B

LTM EBITDA $297M

EV

$2.1B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

TOWA Pharmaceutical Financials

TOWA Pharmaceutical has a last 12-month revenue of $1.7B and a last 12-month EBITDA of $297M.

In the most recent fiscal year, TOWA Pharmaceutical achieved revenue of $1.5B and an EBITDA of $288M.

TOWA Pharmaceutical expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See TOWA Pharmaceutical valuation multiples based on analyst estimates

TOWA Pharmaceutical P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $1.4B $1.5B XXX XXX XXX
Gross Profit $466M $483M XXX XXX XXX
Gross Margin 34% 32% XXX XXX XXX
EBITDA $164M $288M XXX XXX XXX
EBITDA Margin 12% 19% XXX XXX XXX
Net Profit $106M $14.6M XXX XXX XXX
Net Margin 8% 1% XXX XXX XXX
Net Debt $717M $912M XXX XXX XXX

Financial data powered by Morningstar, Inc.

TOWA Pharmaceutical Stock Performance

As of April 15, 2025, TOWA Pharmaceutical's stock price is JPY 2439 (or $16).

TOWA Pharmaceutical has current market cap of JPY 120B (or $798M), and EV of JPY 314B (or $2.1B).

See TOWA Pharmaceutical trading valuation data

TOWA Pharmaceutical Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.1B $798M XXX XXX XXX XXX $2.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

TOWA Pharmaceutical Valuation Multiples

As of April 15, 2025, TOWA Pharmaceutical has market cap of $798M and EV of $2.1B.

TOWA Pharmaceutical's trades at 1.2x LTM EV/Revenue multiple, and 7.0x LTM EBITDA.

Analysts estimate TOWA Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for TOWA Pharmaceutical and 10K+ public comps

TOWA Pharmaceutical Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.1B XXX XXX XXX
EV/Revenue 1.2x XXX XXX XXX
EV/EBITDA 7.1x XXX XXX XXX
P/E 7.5x XXX XXX XXX
P/E/Growth 3.5x XXX XXX XXX
EV/FCF -14.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get TOWA Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

TOWA Pharmaceutical Valuation Multiples

TOWA Pharmaceutical's NTM/LTM revenue growth is 5%

TOWA Pharmaceutical's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, TOWA Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate TOWA Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for TOWA Pharmaceutical and other 10K+ public comps

TOWA Pharmaceutical Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 9% XXX XXX XXX XXX
EBITDA Margin 18% XXX XXX XXX XXX
EBITDA Growth 76% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 22% XXX XXX XXX XXX
Revenue per Employee $0.5M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 28% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

TOWA Pharmaceutical Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

TOWA Pharmaceutical M&A and Investment Activity

TOWA Pharmaceutical acquired  XXX companies to date.

Last acquisition by TOWA Pharmaceutical was  XXXXXXXX, XXXXX XXXXX XXXXXX . TOWA Pharmaceutical acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by TOWA Pharmaceutical

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About TOWA Pharmaceutical

When was TOWA Pharmaceutical founded? TOWA Pharmaceutical was founded in 1957.
Where is TOWA Pharmaceutical headquartered? TOWA Pharmaceutical is headquartered in Japan.
How many employees does TOWA Pharmaceutical have? As of today, TOWA Pharmaceutical has 3.1K+ employees.
Is TOWA Pharmaceutical publicy listed? Yes, TOWA Pharmaceutical is a public company listed on TKS.
What is the stock symbol of TOWA Pharmaceutical? TOWA Pharmaceutical trades under 4553 ticker.
When did TOWA Pharmaceutical go public? TOWA Pharmaceutical went public in 2004.
Who are competitors of TOWA Pharmaceutical? Similar companies to TOWA Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of TOWA Pharmaceutical? TOWA Pharmaceutical's current market cap is $798M
What is the current revenue of TOWA Pharmaceutical? TOWA Pharmaceutical's last 12-month revenue is $1.7B.
What is the current EBITDA of TOWA Pharmaceutical? TOWA Pharmaceutical's last 12-month EBITDA is $297M.
What is the current EV/Revenue multiple of TOWA Pharmaceutical? Current revenue multiple of TOWA Pharmaceutical is 1.2x.
What is the current EV/EBITDA multiple of TOWA Pharmaceutical? Current EBITDA multiple of TOWA Pharmaceutical is 7.0x.
What is the current revenue growth of TOWA Pharmaceutical? TOWA Pharmaceutical revenue growth between 2023 and 2024 was 9%.
Is TOWA Pharmaceutical profitable? Yes, TOWA Pharmaceutical is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.